RU2000106597A - NEW APPLICATION OF BUDESONIDE AND FORMOTHEROL - Google Patents
NEW APPLICATION OF BUDESONIDE AND FORMOTHEROLInfo
- Publication number
- RU2000106597A RU2000106597A RU2000106597/14A RU2000106597A RU2000106597A RU 2000106597 A RU2000106597 A RU 2000106597A RU 2000106597/14 A RU2000106597/14 A RU 2000106597/14A RU 2000106597 A RU2000106597 A RU 2000106597A RU 2000106597 A RU2000106597 A RU 2000106597A
- Authority
- RU
- Russia
- Prior art keywords
- active ingredient
- solvate
- pharmaceutically acceptable
- pulmonary disease
- chronic obstructive
- Prior art date
Links
- VOVIALXJUBGFJZ-VXKMTNQYSA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-VXKMTNQYSA-N 0.000 title claims 5
- 229960004436 Budesonide Drugs 0.000 title claims 5
- 239000004480 active ingredient Substances 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 8
- 239000011780 sodium chloride Substances 0.000 claims 8
- 239000012453 solvate Substances 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 6
- BPZSYCZIITTYBL-YJYMSZOUSA-N Formoterol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-YJYMSZOUSA-N 0.000 claims 4
- 229960002848 formoterol Drugs 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 239000000654 additive Substances 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- ZDUPYZMAPCZGJO-NSCGSSGESA-N (E)-but-2-enedioic acid;N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide Chemical group OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 ZDUPYZMAPCZGJO-NSCGSSGESA-N 0.000 claims 1
- 230000000996 additive Effects 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 229960003610 formoterol fumarate dihydrate Drugs 0.000 claims 1
Claims (10)
(а) первый активный ингредиент, который представляет собой формотерол, его фармацевтически приемлемые соль или сольват или сольват такой соли;
(б) второй активный ингредиент, который представляет собой будезонид; и
молярное соотношение первого активного ингредиента и второго активного ингредиента составляет от 1: 2500 до 12:1, при изготовлении лекарства для использования при лечении хронического обструктивного заболевания легких.1. The use of a composition comprising a mixture or separately:
(a) the first active ingredient, which is formoterol, its pharmaceutically acceptable salt or solvate or the solvate of such a salt;
(b) the second active ingredient, which is budesonide; and
the molar ratio of the first active ingredient and the second active ingredient is from 1: 2500 to 12: 1, in the manufacture of a medicine for use in treating chronic obstructive pulmonary disease.
(1) сосуд, содержащий первый активный ингредиент, который представляет собой формотерол, его фармацевтически приемлемые соль или сольват или сольват такой соли;
(2) сосуд, содержащий второй активный ингредиент, который представляет собой будезонид;
(3) молярное соотношение первого активного ингредиента и второго активного ингредиента составляет от 1:2500 до 12:1; и
(4) инструкции для одновременного, последовательного или раздельного введения первого и второго активных ингредиентов пациенту, нуждающемуся в этом;
при изготовлении лекарства для использования при лечении хронического обструктивного заболевания легких.3. Application of a kit containing:
(1) a vessel containing the first active ingredient, which is formoterol, a pharmaceutically acceptable salt thereof, or a solvate or a solvate of such a salt;
(2) a vessel containing the second active ingredient, which is budesonide;
(3) the molar ratio of the first active ingredient and the second active ingredient is from 1: 2500 to 12: 1; and
(4) instructions for the simultaneous, sequential or separate administration of the first and second active ingredients to a patient in need thereof;
in the manufacture of drugs for use in the treatment of chronic obstructive pulmonary disease.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9703407A SE9703407D0 (en) | 1997-09-19 | 1997-09-19 | New use |
| SE9703407-8 | 1997-09-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2000106597A true RU2000106597A (en) | 2001-12-27 |
| RU2199322C2 RU2199322C2 (en) | 2003-02-27 |
Family
ID=20408325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2000106597/14A RU2199322C2 (en) | 1997-09-19 | 1998-09-09 | Novel application of budesonide and formoterol |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US7897646B2 (en) |
| EP (2) | EP1210943B1 (en) |
| JP (1) | JP2001517630A (en) |
| KR (1) | KR20010024140A (en) |
| CN (1) | CN1149998C (en) |
| AR (1) | AR013506A1 (en) |
| AT (2) | ATE329599T1 (en) |
| AU (1) | AU757235B2 (en) |
| BR (1) | BR9812325A (en) |
| CA (1) | CA2302700C (en) |
| CY (1) | CY1106156T1 (en) |
| CZ (1) | CZ295250B6 (en) |
| DE (2) | DE69807239T2 (en) |
| DK (2) | DK1210943T3 (en) |
| EE (1) | EE04297B1 (en) |
| ES (2) | ES2266322T3 (en) |
| HK (1) | HK1045812B (en) |
| HU (1) | HUP0003848A2 (en) |
| ID (1) | ID24838A (en) |
| IL (1) | IL134773A (en) |
| IN (1) | IN190791B (en) |
| IS (1) | IS2715B (en) |
| MX (1) | MXPA00002615A (en) |
| MY (1) | MY127812A (en) |
| NO (1) | NO327176B1 (en) |
| NZ (1) | NZ503173A (en) |
| PL (1) | PL190782B1 (en) |
| PT (2) | PT1210943E (en) |
| RU (1) | RU2199322C2 (en) |
| SA (1) | SA98190773B1 (en) |
| SE (1) | SE9703407D0 (en) |
| SI (2) | SI1014993T1 (en) |
| SK (1) | SK285330B6 (en) |
| TR (1) | TR200000726T2 (en) |
| TW (1) | TW546140B (en) |
| UA (1) | UA72446C2 (en) |
| WO (1) | WO1999015182A1 (en) |
| ZA (1) | ZA988516B (en) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9703407D0 (en) | 1997-09-19 | 1997-09-19 | Astra Ab | New use |
| SE9802073D0 (en) | 1998-06-11 | 1998-06-11 | Astra Ab | New use |
| CA2347856C (en) * | 1998-11-13 | 2009-02-17 | Jago Research Ag | Dry powder for inhalation |
| US6004537A (en) * | 1998-12-18 | 1999-12-21 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol |
| GB9928311D0 (en) * | 1999-11-30 | 2000-01-26 | Novartis Ag | Organic compounds |
| GB0009584D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Pharmaceutical compositions |
| GB0012261D0 (en) | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel process |
| GB0012260D0 (en) | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel composition |
| DE60221640T2 (en) * | 2001-02-06 | 2008-05-21 | Innovata Biomed Ltd., St. Albans | BIMODAL DRY POWDER COMPOSITION FOR INHALATION |
| US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| SE0200312D0 (en) | 2002-02-01 | 2002-02-01 | Astrazeneca Ab | Novel composition |
| CA2500065A1 (en) * | 2002-09-30 | 2004-04-15 | Acusphere, Inc. | Sustained release porous microparticles for inhalation |
| US6962006B2 (en) * | 2002-12-19 | 2005-11-08 | Acusphere, Inc. | Methods and apparatus for making particles using spray dryer and in-line jet mill |
| US20040121003A1 (en) * | 2002-12-19 | 2004-06-24 | Acusphere, Inc. | Methods for making pharmaceutical formulations comprising deagglomerated microparticles |
| TWI359675B (en) | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
| ES2384641T3 (en) | 2005-07-14 | 2012-07-10 | Lithera, Inc. | Lipolytic formulation that enhances the release maintained for the localized treatment of adipose tissue |
| EP1978933A2 (en) * | 2005-12-15 | 2008-10-15 | Acusphere, Inc. | Processes for making particle-based pharmaceutical formulations for oral administration |
| US7913223B2 (en) * | 2005-12-16 | 2011-03-22 | Dialogic Corporation | Method and system for development and use of a user-interface for operations, administration, maintenance and provisioning of a telecommunications system |
| GB0604141D0 (en) * | 2006-03-01 | 2006-04-12 | Arrow Int Ltd | Nebulizer formulation |
| JP2010506941A (en) * | 2006-10-17 | 2010-03-04 | リセラ，インク． | Methods, compositions and formulations for the treatment of thyroid ophthalmopathy |
| US9132084B2 (en) * | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
| US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| LT2435025T (en) | 2009-05-29 | 2016-09-26 | Pearl Therapeutics, Inc. | Respiratory delivery of active agents |
| WO2010144628A2 (en) * | 2009-06-09 | 2010-12-16 | Elevation Pharmaceuticals, Inc. | Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration |
| CN102000090A (en) * | 2009-08-31 | 2011-04-06 | 北京利乐生制药科技有限公司 | Compound preparation with Budesonide and Arformoterol as active ingredients |
| KR20120113267A (en) * | 2010-01-15 | 2012-10-12 | 리쎄라 인코오포레이티드 | Lyophilized cake formulations |
| EA201270784A1 (en) | 2010-11-24 | 2013-04-30 | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" | MONOTHERAPE TREATMENT COMPOSITIONS OF SELECTIVE LIPOPHIL AND BETA-AGONIST OF LONG ACTION AND METHODS OF COSMETIC TREATMENT FOR OBESITY AND COUNTER-ROOTING |
| CA2830069C (en) | 2011-03-20 | 2019-11-12 | The University Of British Columbia | Therapeutic agent for emphysema and copd |
| CN102362860A (en) * | 2011-10-27 | 2012-02-29 | 江阴长风医药科技有限公司 | Budesonide and formoterol aerosol preparation taking hydro-fluoro-alkane as propellant |
| JP6454323B2 (en) | 2013-03-15 | 2019-01-16 | パール セラピューティクス，インコーポレイテッド | Method and system for conditioning particulate crystalline materials |
| ITMI20130571A1 (en) * | 2013-04-10 | 2014-10-11 | Zambon Spa | PHARMACEUTICAL COMPOSITION CONTAINING BUDESONIDE AND FORMOTEROL |
| WO2015065220A1 (en) * | 2013-10-28 | 2015-05-07 | Шолекс Девелопмент Гмбх | Inhaled drug for the treatment of bronchial asthma and chronic obstructive pulmonary disease and method for producing same |
| GB201321717D0 (en) | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Inhalable Medicaments |
| GB201321712D0 (en) | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Dry Powder Inhaler |
| GB201408387D0 (en) * | 2014-05-12 | 2014-06-25 | Teva Pharmaceuticals Europ B V | Treatment of respiratory disorders |
| CA3007050C (en) | 2015-12-04 | 2020-12-08 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition comprising a formoterol compound |
| AU2019287541A1 (en) | 2018-06-14 | 2021-01-21 | Astrazeneca Uk Limited | Methods for treating and preventing symptoms of asthma with a corticosteroid pharmaceutical composition |
| WO2021048171A1 (en) * | 2019-09-10 | 2021-03-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to improve phagocytosis |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2235626B (en) | 1989-09-08 | 1994-02-09 | Glaxo Group Ltd | Inhalation medicaments for treating respiratory disorders |
| IL95590A (en) | 1989-09-08 | 1996-06-18 | Glaxo Group Ltd | Pharmaceutical compositions comprising salmeterol and fluticasone propionate |
| US5250286A (en) | 1990-05-07 | 1993-10-05 | Aegis Technology, Inc. | Treatment of chronic obstructive pulmonary disease (COPD) by inhalation of an imidazoline |
| PL164294B1 (en) | 1990-12-20 | 1994-07-29 | Inst Farmaceutyczny | Method of obtaining a diasteroisomer (22r) of budezonide |
| US5795564A (en) | 1991-04-05 | 1998-08-18 | Sepracor, Inc. | Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol |
| US5444521A (en) | 1991-07-15 | 1995-08-22 | Canon Kabushiki Kaisha | Image fixing device capable of controlling heating overshoot |
| EP1086697A2 (en) | 1991-12-18 | 2001-03-28 | AstraZeneca AB | New combination of formoterol and budesonide |
| NZ246050A (en) * | 1991-12-18 | 1995-12-21 | Astra Ab Formerly Aktiebolaget | Medicament containing formoterol and budesonide for treatment of respiratory disorders |
| SE9404080L (en) | 1993-12-28 | 1995-06-29 | Ciba Geigy Ag | Process for preparing an optically pure enantiomer of formoterol |
| SE9700134D0 (en) | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| US5983956A (en) | 1994-10-03 | 1999-11-16 | Astra Aktiebolag | Formulation for inhalation |
| GB9519692D0 (en) | 1995-09-27 | 1995-11-29 | Quillin Helen | Atomising nozzle |
| CA2238298A1 (en) * | 1995-11-24 | 1997-06-19 | Luca Francesco Raveglia | Quinoline derivatives |
| SE9603669D0 (en) | 1996-10-08 | 1996-10-08 | Astra Ab | New combination |
| SE9700135D0 (en) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| PL337722A1 (en) | 1997-06-27 | 2000-08-28 | Astra Ab | Novel combination antiasthmatic drugs |
| SE9703407D0 (en) * | 1997-09-19 | 1997-09-19 | Astra Ab | New use |
| US6598603B1 (en) * | 1997-12-31 | 2003-07-29 | Astra Aktiebolag | Method for treating respiratory diseases |
| SE9802073D0 (en) | 1998-06-11 | 1998-06-11 | Astra Ab | New use |
| DZ2947A1 (en) | 1998-11-25 | 2004-03-15 | Chiesi Farma Spa | Pressure metered dose inhaler. |
| US6004537A (en) | 1998-12-18 | 1999-12-21 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol |
| SE9900834D0 (en) | 1999-03-09 | 1999-03-09 | Astra Ab | Novel combination |
-
1997
- 1997-09-19 SE SE9703407A patent/SE9703407D0/en unknown
-
1998
- 1998-09-09 DK DK02001670T patent/DK1210943T3/en active
- 1998-09-09 PT PT02001670T patent/PT1210943E/en unknown
- 1998-09-09 RU RU2000106597/14A patent/RU2199322C2/en active
- 1998-09-09 KR KR1020007002900A patent/KR20010024140A/en not_active Application Discontinuation
- 1998-09-09 EP EP02001670A patent/EP1210943B1/en not_active Revoked
- 1998-09-09 IL IL13477398A patent/IL134773A/en not_active IP Right Cessation
- 1998-09-09 AT AT02001670T patent/ATE329599T1/en not_active IP Right Cessation
- 1998-09-09 DE DE69807239T patent/DE69807239T2/en not_active Revoked
- 1998-09-09 ES ES02001670T patent/ES2266322T3/en not_active Expired - Lifetime
- 1998-09-09 ID IDW20000506A patent/ID24838A/en unknown
- 1998-09-09 HU HU0003848A patent/HUP0003848A2/en not_active Application Discontinuation
- 1998-09-09 MX MXPA00002615A patent/MXPA00002615A/en active IP Right Grant
- 1998-09-09 JP JP2000512551A patent/JP2001517630A/en active Pending
- 1998-09-09 SI SI9830272T patent/SI1014993T1/en unknown
- 1998-09-09 ES ES98944373T patent/ES2182357T3/en not_active Expired - Lifetime
- 1998-09-09 CA CA2302700A patent/CA2302700C/en not_active Expired - Lifetime
- 1998-09-09 AT AT98944373T patent/ATE222106T1/en not_active IP Right Cessation
- 1998-09-09 EP EP98944373A patent/EP1014993B1/en not_active Revoked
- 1998-09-09 EE EEP200000145A patent/EE04297B1/en unknown
- 1998-09-09 BR BR9812325-4A patent/BR9812325A/en not_active Application Discontinuation
- 1998-09-09 CZ CZ2000950A patent/CZ295250B6/en not_active IP Right Cessation
- 1998-09-09 CN CNB988093103A patent/CN1149998C/en not_active Expired - Lifetime
- 1998-09-09 NZ NZ503173A patent/NZ503173A/en not_active IP Right Cessation
- 1998-09-09 WO PCT/SE1998/001599 patent/WO1999015182A1/en not_active Application Discontinuation
- 1998-09-09 SK SK389-2000A patent/SK285330B6/en not_active IP Right Cessation
- 1998-09-09 TR TR2000/00726T patent/TR200000726T2/en unknown
- 1998-09-09 DK DK98944373T patent/DK1014993T3/en active
- 1998-09-09 DE DE69834955T patent/DE69834955T2/en not_active Revoked
- 1998-09-09 PL PL339295A patent/PL190782B1/en unknown
- 1998-09-09 PT PT98944373T patent/PT1014993E/en unknown
- 1998-09-09 UA UA2000031372A patent/UA72446C2/en unknown
- 1998-09-09 AU AU91928/98A patent/AU757235B2/en not_active Expired
- 1998-09-09 SI SI9830844T patent/SI1210943T1/en unknown
- 1998-09-16 TW TW087115428A patent/TW546140B/en not_active IP Right Cessation
- 1998-09-16 IN IN2781DE1998 patent/IN190791B/en unknown
- 1998-09-17 ZA ZA988516A patent/ZA988516B/en unknown
- 1998-09-18 MY MYPI98004288A patent/MY127812A/en unknown
- 1998-09-18 AR ARP980104682A patent/AR013506A1/en unknown
- 1998-11-18 SA SA98190773A patent/SA98190773B1/en unknown
-
2000
- 2000-03-15 IS IS5407A patent/IS2715B/en unknown
- 2000-03-17 NO NO20001401A patent/NO327176B1/en not_active IP Right Cessation
-
2001
- 2001-11-13 US US10/010,283 patent/US7897646B2/en not_active Expired - Fee Related
-
2002
- 2002-10-03 HK HK02107290.0A patent/HK1045812B/en not_active IP Right Cessation
-
2006
- 2006-09-12 CY CY20061101297T patent/CY1106156T1/en unknown
-
2010
- 2010-12-30 US US12/982,360 patent/US8461211B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2000106597A (en) | NEW APPLICATION OF BUDESONIDE AND FORMOTHEROL | |
| CA2302700A1 (en) | New use for budesonide and formoterol | |
| KR101161889B1 (en) | Use of treprostinil to treat and prevent ischemic lesions | |
| RU2000131218A (en) | APPLICATION OF THE COMPOSITION CONTAINING FORMOTHEROL AND BUDESONIDE FOR THE PREVENTION OR TREATMENT OF ACUTE ASTHMA | |
| RU2003130058A (en) | COMBINATIONS INCLUDING ANTIDIARAH AGENT AND EPOTHYLON OR EPOTHYLON DERIVATIVES | |
| RU95107881A (en) | Pharmaceutical composition for allergic disease treatment, method of antihistamine treatment, use of composition for medicinal preparation preparing | |
| LU90392I2 (en) | A combination comprising salmeterol optionally in the form of a pharmaceutically acceptable salt including 1-hydroxy-2-naphthoate (xinafoate) and fluticasone propionate | |
| WO2005099680A2 (en) | Use of treprostinil to treat neuropathic diabetic foot ulcers | |
| RU2003119545A (en) | PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION OF PHAMACOLOGICAL ACTIVE SUBSTANCES | |
| RU2004105865A (en) | NEW METHOD OF TREATMENT | |
| UA76417C2 (en) | Pharmaceutical composition comprising immediate release phase and sustained release phase of paracetamol | |
| IL273169B1 (en) | New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild) | |
| RU99118588A (en) | A NEW MEDICINE FOR INHALATION, HAVING A FILLING VOLUME DENSITY FROM 0.28 TO 0.38 G / ML, CONTAINING FORMOTEROL | |
| RU2006131553A (en) | COMBINATION (A) OF DNA TOPOISOMERASE INHIBITOR AND (B) IAP INHIBITOR | |
| JP2002528502A5 (en) | ||
| JP2006514092A5 (en) | ||
| CA2072533A1 (en) | Process for the preparation of a pharmaceutical formulation containing at least two different active substances and use of such a formulation | |
| RU95101385A (en) | Products containing g-csf and tnf-binding protein | |
| RU2001111808A (en) | PHARMACEUTICAL COMPOSITION CONTAINING A COMBINATION OF ROTARY AND LEFT ROTARY ISOMERS OF SOTALOL | |
| EP0544760B1 (en) | Pharmaceutical compositions containing 5-difluoromethoxy-2- (3,4-dimethoxy-2-pyridyl) methylsulfinyl] benzimidazole and an anti-helicobacter agent for the treatment of gastrointestinal disorders | |
| RU2005105691A (en) | Oral Administration of Calcitonin | |
| US5278172A (en) | Method and composition for treating tendon or joint inflammation using a vasodilator | |
| HUP0002533A2 (en) | New combination of antiasthma medicaments | |
| RU97120700A (en) | NEW PHARMACOLOGICAL APPLICATION OF ANTAGONISTS A-II RECEPTOR | |
| RU2008108176A (en) | A COMBINATION OF COMPOUNDS THAT MAY BE APPLIED IN THE TREATMENT OF RESPECTIVE DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE DISEASES OF THE LUNG (COPD) AND ASTHMA |